Showing 1765 results
-
Press release /Der Wirkstoff führt zu rascher Parasitenfreiheit auch bei resistenten Erregerstämmen, blockiert die Übertragung der Erreger und könnte damit eine Wende im Kampf gegen Malaria herbeiführen.…
-
Press release /New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
-
Clinical Trials /
-
Ad hoc release /In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
-
Press release /Data suggest myelofibrosis (MF) patients treated with Jakavi® (ruxolitinib) after 5 years lived longer despite crossover from best available therapy after week 48[1] Phase III results show…
-
Press release /Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
-
Press release /Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is…
-
Press release /In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate…
-
Press release /Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra…